Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer: early-phase trial registry
146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #12 of 28,963 conditions by registered trial count.
430 US clinical trials · 146 currently recruiting · #12 of 28,963 conditions by registered trial count
Lung Cancer: 430 US clinical trials tracked, 146 recruiting.
Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.
Open enrollment, early-phase tilt
Lung Cancer has 430 registered US clinical trials, 146 of them open to new participants right now, about 34% of the total.
- 146
- recruiting participants now
- 34%
- of trials open to enrollment
- 23
- in Phase 3-4 (later-stage)
- 36
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #12 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer is recruiting below its size-band peers.
146 of 430 indexed trials (34%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer enrolment sits around 89 participants.
Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.
-
Lung Cancer research is mostly interventional.
321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
430 total, page 5 of 9
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
NCT06187103
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
University of Virginia
NCT05370469
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Memorial Sloan Kettering Cancer Center
NCT03220477
The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia
Pennington Biomedical Research Center
NCT05919147
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
TILT Biotherapeutics
NCT06125197
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT03611738
Study Assessing QBS72S For Treating Brain Metastases
Stanford University
NCT05305365
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Afatinib With CT and RT for EGFR-Mutant NSCLC
Massachusetts General Hospital
NCT01553942
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx
NCT05902520
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
University of California, San Diego
NCT04545710
Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies
Memorial Sloan Kettering Cancer Center
NCT02434809
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT04716946
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
University of Colorado, Denver
NCT05845671
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
NCT03567642
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
NCT02955940
Oncology Episode Payment Model in Hawaii
University of Pennsylvania
NCT03523546
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
University of Nebraska
NCT04748419
A Study Comparing Mindfulness Apps to Decrease Anxiety in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT06008574
National Lung Screening Trial (NLST) Screening
National Cancer Institute (NCI)
NCT00047385
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
Daiichi Sankyo
NCT06557967
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
M.D. Anderson Cancer Center
NCT00453661
S9925: Collecting and Storing Samples From Patients With Lung Cancer
SWOG Cancer Research Network
NCT00920010
An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions
St Elizabeth Healthcare
NCT03535766
Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking
Alliance for Clinical Trials in Oncology
NCT00033592
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
ECOG-ACRIN Cancer Research Group
NCT01107626
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Bristol-Myers Squibb
NCT02847728
Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer
Eastern Cooperative Oncology Group
NCT00002667
Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT01517971
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
SWOG Cancer Research Network
NCT00450281
Evaluation of a Patient 'nudge' on Engagement in Lung Cancer Screening
Kaiser Permanente
NCT06474611
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA
Allegro Diagnostics
NCT01309087
Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung
Auris Health
NCT04182815
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Novartis
NCT00003884
Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning
Susanne Arnold
NCT00596310
Effect of Lung Cancer Diagnoses on Family Behaviors
National Human Genome Research Institute (NHGRI)
NCT01862770
Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer
Massachusetts General Hospital
NCT03337399
DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules
Boston University
NCT01785342
Pleural Catheters Versus Thoracoscopic Pleurodesis
M.D. Anderson Cancer Center
NCT01117740
African American Families and Lung Cancer Study
National Human Genome Research Institute (NHGRI)
NCT00487760
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
Alliance for Clinical Trials in Oncology
NCT00003387
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
NCT00048997
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
SWOG Cancer Research Network
NCT00004011
Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer
University of Minnesota
NCT01673711
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Alliance for Clinical Trials in Oncology
NCT00417040
CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients
Baylor College of Medicine
NCT02414672
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT00004138
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
City of Hope Medical Center
NCT00823732
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 96 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Lung Cancer right now
146 recruiting of 430 indexed (34% open).
Phase mix: 23 late (III/IV) vs 181 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (36 trials), 9 others listed. 50 shown below, recruiting first. #12 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Lung Cancer?
PlainTrial tracks 430 US clinical trials for Lung Cancer, of which 146 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Lung Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.